Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

AllTranz Developing Multi-Use Transdermal Patch

By Drug Discovery Trends Editor | April 15, 2010

AllTranz, Lexington, Ky., is focused on the development of transdermal treatments for pain and other neurological disorders. The lead product in the company pipeline is a synthetic non-psychoactive cannabinoid delivered via gel. The initial indication is for the treatment of osteoarthritis. AllTranz also plans to develop a second generation of this product for the treatment of alcoholism. The gel product for arthritis pain is scheduled for a Phase 1 clinical trial by 2011. Another cannabinoid patch has been funded by the National Institutes of Health through a 2011 Phase 1 clinical trial. An abuse-deterrent opioid patch prototype has also been developed and is scheduled for preclinical toxicology testing in 2010. The AllTranz technology addresses not only pharmacological limitations, but the abuse potential which confounds the utility of current opioids.

AllTranz is focused on the design, synthesis, characterization, and testing of novel prodrugs—drugs with known clinical efficacy needing a chemical modification in order to go through the skin at a sufficient therapeutic rate. Prodrugs are a great method for permeation enhancement as they can improve drug solubility, stability, and potentially decrease skin irritation. AllTranz technical capabilities include drug synthesis (controlled substance schedule I-V), analytical method development (HPLC and LC-MS/MS), biological sample analysis, drug formulation, in vitro human skin diffusion studies, and pharmacokinetic studies in rats, hairless guinea pigs, and miniature swine.

Company intellectual property also includes an adjuvant technology for use with microneedle and other microporation systems, in order to extend single patch treatment duration to one week. Dr. Audra Stinchcomb, founder and chief scientific officer of AllTranz, is actively engaged in leveraging chemical techniques to develop new prodrug formulations and drug delivery platforms using unique transdermal drug delivery vehicles.

AllTranz is also actively pursuing corporate partnerships with companies interested in co-development of transdermal products of mutual interest.

This news was featured in Drug Discovery & Development magazine: Vol. 13, No. 3, April 2010, p. 35.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE